Thymus Transplantation Safety-Efficacy
Completed · Not applicable
Conditions studied: Complete DiGeorge Anomaly, DiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge Syndrome
In brief
Complete DiGeorge anomaly (cDGA) is a disorder in which there is no thymus function. With no thymus function, bone marrow stem cells do not develop into educated T cells, which fight infection. Without successful treatment, patients with cDGA must remain in reverse isolation to prevent infection and subsequent death. Cultured thymus tissue with and without immunosuppression (drugs given before and after implantation) has resulted in the development of good T cell function in subjects with complete DiGeorge anomaly. This expanded access study continues cultured thymus tissue safety and efficacy research for the treatment of complete DiGeorge anomaly. Eligible participants receive cultured thymus tissue. Immune function testing is continued for one year post-implantation.
Key facts
- Study ID
- NCT01220531
- Run by
- Sumitomo Pharma Switzerland GmbH
- People needed
- 29
- Starts
- 2010-12-01
- Expected to finish
- 2023-08-01
- Last updated by the study team
- 2025-01-16
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- John W. Sleasman — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.